Revolutionizing Prostate Cancer Treatment with Actinium-Based Drug

Novartis reports promising early data from an experimental actinium-based drug for prostate cancer, showing significant PSA level reductions in patients, including those treated with its previous drug Pluvicto. More research is needed to assess side effects, but the company is advancing radioligand therapies with substantial R&D investments.

Novartis has announced encouraging early data from a study of its experimental actinium-based drug for prostate cancer, showing potential anti-tumor activity. The study revealed that 52.5% of patients previously treated with Novartis’ older drug, Pluvicto, experienced a dramatic reduction in their prostate-specific antigen (PSA) levels by at least half.

Patients who hadn't been treated with Pluvicto exhibited even higher response rates. Over 85% of those with no prior treatment and nearly 59% of patients who had first undergone chemotherapy saw their PSA levels drop significantly, as reported at the American Society of Clinical Oncology meeting. Analysts emphasized the treatment's efficacy but noted potential side effects including severe dry mouth and anemia, highlighting the need for cautious management.

According to Novartis Chief Medical Officer Shreeram Aradhye, further trials will be imperative to fully understand the side effects, especially if the drug is used earlier in treatment stages. Novartis is moving forward with late-stage studies of the drug, with radioligand therapies comprising a significant portion of its cancer research and development investments. Radiopharma, a burgeoning field in cancer treatment, is attracting interest from other pharma giants like Eli Lilly and AstraZeneca.